Cargando…

Synthesis of the cyanobacterial halometabolite Chlorosphaerolactylate B and demonstration of its antimicrobial effect in vitro and in vivo

Chlorosphaerolactylate B, a newly discovered antimicrobial halometabolite from the cyanobacterium Sphaerospermopsis sp. LEGE 00249 has been synthesized in three steps by using 12-bromododecanoic acid as starting material. A total of 0.5 g was produced for in vitro and in vivo antimicrobial efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Nikoline, Jensen, Henrik Elvang, Aalbaek, Bent, Blirup-Plum, Sophie Amalie, Soto, Sara M., Cepas, Virginio, López, Yuly, Gabasa, Yaiza, Gutiérrez-del-Río, Ignacio, Villar, Claudio J., Lombó, Felipe, Iglesias, María José, Soengas, Raquel, López Ortiz, Fernando, Jensen, Louise Kruse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557163/
https://www.ncbi.nlm.nih.gov/pubmed/36246241
http://dx.doi.org/10.3389/fmicb.2022.950855
_version_ 1784807242929799168
author Jensen, Nikoline
Jensen, Henrik Elvang
Aalbaek, Bent
Blirup-Plum, Sophie Amalie
Soto, Sara M.
Cepas, Virginio
López, Yuly
Gabasa, Yaiza
Gutiérrez-del-Río, Ignacio
Villar, Claudio J.
Lombó, Felipe
Iglesias, María José
Soengas, Raquel
López Ortiz, Fernando
Jensen, Louise Kruse
author_facet Jensen, Nikoline
Jensen, Henrik Elvang
Aalbaek, Bent
Blirup-Plum, Sophie Amalie
Soto, Sara M.
Cepas, Virginio
López, Yuly
Gabasa, Yaiza
Gutiérrez-del-Río, Ignacio
Villar, Claudio J.
Lombó, Felipe
Iglesias, María José
Soengas, Raquel
López Ortiz, Fernando
Jensen, Louise Kruse
author_sort Jensen, Nikoline
collection PubMed
description Chlorosphaerolactylate B, a newly discovered antimicrobial halometabolite from the cyanobacterium Sphaerospermopsis sp. LEGE 00249 has been synthesized in three steps by using 12-bromododecanoic acid as starting material. A total of 0.5 g was produced for in vitro and in vivo antimicrobial efficacy testing. In vitro, the minimal inhibitory concentration (MIC) was estimated to be 256 mg/L for Staphylococcus aureus, while the minimal biofilm inhibitory concentration (MBIC) was estimated to be 74 mg/L. The in vivo study utilized a porcine model of implant-associated osteomyelitis. In total, 12 female pigs were allocated into 3 groups based on inoculum (n = 4 in each group). An implant cavity (IC) was drilled in the right tibia and followed by inoculation and insertion of a steel implant. All pigs were inoculated with 10 μL containing either: 11.79 mg synthetic Chlorosphaerolactylate B + 10(4) CFU of S. aureus (Group A), 10(4) CFU of S. aureus (Group B), or pure saline (Group C), respectively. Pigs were euthanized five days after inoculation. All Group B animals showed macroscopic and microscopic signs of bone infection and both tissue and implant harbored S. aureus bacteria (mean CFU on implants = 1.9 × 10(5)). In contrast, S. aureus could not be isolated from animals inoculated with saline. In Group A, two animals had a low number of S. aureus (CFU = 6.7 × 10(1) and 3.8 × 10(1), respectively) on the implants, otherwise all Group A animals were similar to Group C animals. In conclusion, synthetic Chlorosphaerolactylate B holds potential to be a novel antimicrobial and antibiofilm compound.
format Online
Article
Text
id pubmed-9557163
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95571632022-10-14 Synthesis of the cyanobacterial halometabolite Chlorosphaerolactylate B and demonstration of its antimicrobial effect in vitro and in vivo Jensen, Nikoline Jensen, Henrik Elvang Aalbaek, Bent Blirup-Plum, Sophie Amalie Soto, Sara M. Cepas, Virginio López, Yuly Gabasa, Yaiza Gutiérrez-del-Río, Ignacio Villar, Claudio J. Lombó, Felipe Iglesias, María José Soengas, Raquel López Ortiz, Fernando Jensen, Louise Kruse Front Microbiol Microbiology Chlorosphaerolactylate B, a newly discovered antimicrobial halometabolite from the cyanobacterium Sphaerospermopsis sp. LEGE 00249 has been synthesized in three steps by using 12-bromododecanoic acid as starting material. A total of 0.5 g was produced for in vitro and in vivo antimicrobial efficacy testing. In vitro, the minimal inhibitory concentration (MIC) was estimated to be 256 mg/L for Staphylococcus aureus, while the minimal biofilm inhibitory concentration (MBIC) was estimated to be 74 mg/L. The in vivo study utilized a porcine model of implant-associated osteomyelitis. In total, 12 female pigs were allocated into 3 groups based on inoculum (n = 4 in each group). An implant cavity (IC) was drilled in the right tibia and followed by inoculation and insertion of a steel implant. All pigs were inoculated with 10 μL containing either: 11.79 mg synthetic Chlorosphaerolactylate B + 10(4) CFU of S. aureus (Group A), 10(4) CFU of S. aureus (Group B), or pure saline (Group C), respectively. Pigs were euthanized five days after inoculation. All Group B animals showed macroscopic and microscopic signs of bone infection and both tissue and implant harbored S. aureus bacteria (mean CFU on implants = 1.9 × 10(5)). In contrast, S. aureus could not be isolated from animals inoculated with saline. In Group A, two animals had a low number of S. aureus (CFU = 6.7 × 10(1) and 3.8 × 10(1), respectively) on the implants, otherwise all Group A animals were similar to Group C animals. In conclusion, synthetic Chlorosphaerolactylate B holds potential to be a novel antimicrobial and antibiofilm compound. Frontiers Media S.A. 2022-09-29 /pmc/articles/PMC9557163/ /pubmed/36246241 http://dx.doi.org/10.3389/fmicb.2022.950855 Text en Copyright © 2022 Jensen, Jensen, Aalbaek, Blirup-Plum, Soto, Cepas, López, Gabasa, Gutiérrez-del-Río, Villar, Lombó, Iglesias, Soengas, López Ortiz and Jensen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Jensen, Nikoline
Jensen, Henrik Elvang
Aalbaek, Bent
Blirup-Plum, Sophie Amalie
Soto, Sara M.
Cepas, Virginio
López, Yuly
Gabasa, Yaiza
Gutiérrez-del-Río, Ignacio
Villar, Claudio J.
Lombó, Felipe
Iglesias, María José
Soengas, Raquel
López Ortiz, Fernando
Jensen, Louise Kruse
Synthesis of the cyanobacterial halometabolite Chlorosphaerolactylate B and demonstration of its antimicrobial effect in vitro and in vivo
title Synthesis of the cyanobacterial halometabolite Chlorosphaerolactylate B and demonstration of its antimicrobial effect in vitro and in vivo
title_full Synthesis of the cyanobacterial halometabolite Chlorosphaerolactylate B and demonstration of its antimicrobial effect in vitro and in vivo
title_fullStr Synthesis of the cyanobacterial halometabolite Chlorosphaerolactylate B and demonstration of its antimicrobial effect in vitro and in vivo
title_full_unstemmed Synthesis of the cyanobacterial halometabolite Chlorosphaerolactylate B and demonstration of its antimicrobial effect in vitro and in vivo
title_short Synthesis of the cyanobacterial halometabolite Chlorosphaerolactylate B and demonstration of its antimicrobial effect in vitro and in vivo
title_sort synthesis of the cyanobacterial halometabolite chlorosphaerolactylate b and demonstration of its antimicrobial effect in vitro and in vivo
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557163/
https://www.ncbi.nlm.nih.gov/pubmed/36246241
http://dx.doi.org/10.3389/fmicb.2022.950855
work_keys_str_mv AT jensennikoline synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT jensenhenrikelvang synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT aalbaekbent synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT blirupplumsophieamalie synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT sotosaram synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT cepasvirginio synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT lopezyuly synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT gabasayaiza synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT gutierrezdelrioignacio synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT villarclaudioj synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT lombofelipe synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT iglesiasmariajose synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT soengasraquel synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT lopezortizfernando synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo
AT jensenlouisekruse synthesisofthecyanobacterialhalometabolitechlorosphaerolactylatebanddemonstrationofitsantimicrobialeffectinvitroandinvivo